Samuels - Lab

Thank you @Nofar74793338!

Here at the Samuels lab we believe in safety first! #Lentivirus #SafetyFirst #LabLife

Proud of @samuels_yardena for her fascinating plenary session at the @AACR annual meeting in Chicago! A great thank you to the program committee chairs, Drs. Matthew G. Vander Heiden and Lillian L. Siu for this amazing opportunity. @mvh_lab @lillian_siu #AACR25 #AACR2025

Translation dysregulation may serve as a new source for identifying cancer-associated antigens, and may also help to predict responses to checkpoint blockade bit.ly/3E4OMY8  @chen_weller  @samuels_yardena @Samuels_lab #CheckpointBlockade #CancerImmunotherapy

Thrilled to share our work in Cancer Cell! Huge thanks to my PI and mentor @samuels_yardena ,OsnatBartok, and our collaborators @chrismcginnis,@Satpathology , Andreas Schlosser,@EytanRuppin & more. We reveal how impaired translation fidelity enhances anti-tumor immunity!🧵(1/8)

In a study published in @Cancer_Cell, researchers from @Samuels_lab manipulated cancer cells into making themselves visible to the immune system, creating a new approach that gives hope to patients with previously untreatable disease>>bit.ly/cancer-expose-… @samuels_yardena

AACR - The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity @AACR @samuels_yardena oncodaily.com/blog/intratumo… #Cancer #CancerResearch #AACR #MedX #MedNews #MedEd #IntratumorHeterogeneity #Medicine #Health #Oncology #OncoDaily

The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity: Yardena Samuels will address this topic in a plenary session on Targeting the Cancer Ecosystem (Tuesday, April 29) at #AACR25. Learn more: brnw.ch/21wRxxa @samuels_yardena

8/8 All this would not be possible without the hard work of Sapir Cohen Shvefel, @joyp_ai @sathpathology @NCIEytanRuppin, @samuels_yardena and colleagues. @weizmannScience #CancerResearch #Immunotherapy

7/8 Our findings suggest that MIF expression is an important determinant of aggressive tumor growth in low-ITH tumors in melanoma and could lead to new strategies for treating patients with homogeneous, high-MIF-expressing tumors that don't respond to immune checkpoint therapy.

Our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @CD_AACR (full study here:aacrjournals.org/cancerdiscover…) Step-by-step breakdown of this exciting research follows:

New study in @Samuels_lab, published in Cancer Discovery, reveals a key player in the development of aggressive melanoma tumors: a small immune system protein called Mif. Findings promise to open new directions of therapy >> bit.ly/3F8O8sK @samuels_yardena

Congratulations to our very own Sapir Cohen Shvefel! Her paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in #melanoma, is now published in @CD_AACR ! Full article here: aacrjournals.org/cancerdiscover…

Thrilled to share that our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @Cancer Discovery! Find the full study here: aacrjournals.org/cancerdiscover…